Amgen (BSP:AMGN34) Days Payable : 59.99 (As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Amgen Days Payable?

Amgen's average Accounts Payable for the three months ended in Sep. 2024 was R$12,050 Mil. Amgen's Cost of Goods Sold for the three months ended in Sep. 2024 was R$18,330 Mil. Hence, Amgen's Days Payable for the three months ended in Sep. 2024 was 59.99.

The historical rank and industry rank for Amgen's Days Payable or its related term are showing as below:

BSP:AMGN34' s Days Payable Range Over the Past 10 Years
Min: 51.04 Med: 83.22 Max: 113.88
Current: 51.04

During the past 13 years, Amgen's highest Days Payable was 113.88. The lowest was 51.04. And the median was 83.22.

BSP:AMGN34's Days Payable is ranked worse than
72.93% of 953 companies
in the Drug Manufacturers industry
Industry Median: 85.16 vs BSP:AMGN34: 51.04

Amgen's Days Payable declined from Sep. 2023 (64.40) to Sep. 2024 (59.99). It may suggest that Amgen accelerated paying its suppliers.

Amgen Days Payable Historical Data

The historical data trend for Amgen's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Days Payable Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

105.28

74.52

75.18

86.74

70.68

Amgen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															64.40	43.38	45.52	53.18	59.99

Competitive Comparison of Amgen's Days Payable

For the Drug Manufacturers - General subindustry, Amgen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Days Payable distribution charts can be found below:

* The bar in red indicates where Amgen's Days Payable falls into.

Amgen Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Amgen's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (8245.769	+	7790.682)	/	2 )	/	41408.21	*	365
=	8018.2255					/	41408.21	*	365
=	70.68

Amgen's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (12210.289	+	11889.657)	/	2 )	/	18330.118	*	365 / 4
=	12049.973					/	18330.118	*	365 / 4
=	59.99

Amgen Days Payable Related Terms

Thank you for viewing the detailed overview of Amgen's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BSP:AMGN34) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico 1AMGN:Italy AMGd:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN:Chile AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Headlines

No Headlines